Fluidx Medical Technology has announced that its Ultra embolic device was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumour at Auckland City Hospital in Auckland, New Zealand. Ultra is designed for embolization of hypervascular tumours and blood vessels to control bleeding in the peripheral vasculature.
The lesion was treated via radial access through a 150cm 2.7Fr Progreat (Terumo) microcatheter with approximately 1.7ml of Ultra. Subsequent magnetic resonance imaging (MRI) the day following the procedure showed complete devascularisation of the treated region.
“When further embolization is necessary in the middle of treatment, the ability to leave your catheter in place and open another ready-to-use syringe, with no preparation, is a significant benefit.” said Brendan Buckley, investigator at Auckland City Hospital. “The haptic feedback from the syringe when delivering Ultra allows precise control when embolizing, especially in complex arterial territories.”
Although more than US$3.5 billion is spent annually on embolic devices to treat tumours, bleeding, and other conditions throughout the body, many of these devices remain difficult to prepare, deliver, and control. Fluidx embolic gels were designed to reshape the clinical experience through their versatility, simplicity, and ability to be delivered using any catheter.
“This case continues to validate the Ultra platform’s performance and safety,” said Russ Bjorklund, vice president, Fluidx Medical Technology. “Ultra was delivered into a range of vessel sizes, achieving consistent filling, which is exactly the kind of predictable performance we built this technology to deliver.”
